Assignee
METRIOPHARM AG
CH·6 granted patents·8 pending applications·4 citations·filing 2014–2024
Top patents by PatentIndex Score
14 records- 0175US11007192B2Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosisMETRIOPHARM AG·Filed 2017·Granted May 18, 2021·2 cites·11 claims
- 0270US2025051288A1Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedioneMETRIOPHARM AG·Filed 2024·Application pending·0 cites
- 0364US9079863B2Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said formsMETRIOPHARM AG·Filed 2014·Granted Jul 14, 2015·1 cites·16 claims
- 0463US10258620B2Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said formMETRIOPHARM AG·Filed 2015·Granted Apr 16, 2019·1 cites·2 claims
- 0559US2026060981A1Combination of 5-amino-2,3-dihydro-1,4-phthalazinedione and a fumaric acid esterMETRIOPHARM AG·Filed 2023·Application pending·0 cites
- 0658US12122753B2Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedioneMETRIOPHARM AG·Filed 2019·Granted Oct 22, 2024·0 cites·8 claims
- 0752US11111218B2Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dioneMETRIOPHARM AG·Filed 2017·Granted Sep 7, 2021·0 cites·9 claims
- 0851US2023241060A1Glucocorticoid-sparing agentMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 0949US2023218614A1Compound for the treatment of coronaviral infectionsMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 1048US2023113516A15-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injuryMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 1147US2023053455A1Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseasesMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 1246US2023061223A1Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseasesMETRIOPHARM AG·Filed 2021·Application pending·0 cites
- 1342US11203575B2Methhod for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dioneMETRIOPHARM AG·Filed 2017·Granted Dec 21, 2021·0 cites·4 claims
- 1440US2024075029A1Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infectionMETRIOPHARM AG·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →